Abstract
A novel approach to gene correction by genome editing shows great promise as a treatment for Duchenne muscular dystrophy (DMD). CRISPR/Cas9 delivered by adeno-associated virus to a mouse model for DMD demonstrated improvement in function and histology.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have